Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

ClinicalTrials.gov ID: NCT05712889

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05712889. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer

Study identification

NCT ID: NCT05712889
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Vincerx Pharma, Inc.; Industry
Enrollment: 29 participants

Conditions and interventions

Conditions

Neoplasms

Interventions

VIP236 (Q3W) Drug
VIP236 (Q2W) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 24, 2023 (Actual)
Primary completion: Oct 10, 2024 (Actual)
Completion: Oct 10, 2024 (Actual)
Last update posted: Nov 15, 2024

2023 – 2024

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 3

Facility	City	State	ZIP	Site status
Honor Health	Scottsdale	Arizona	85258	—
NEXT Austin	Austin	Texas	78758	—
NEXT Oncology San Antonio	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05712889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 15, 2024 · Synced Nov 15, 2026